Marketing authorisation of orphan medicines in Europe from 2000 to 2013
- PMID: 29074441
- DOI: 10.1016/j.drudis.2017.10.012
Marketing authorisation of orphan medicines in Europe from 2000 to 2013
Abstract
An analysis was performed on a data set of 157 orphan designated medicines with an outcome for marketing authorisation application (MAA) between 2000 and 2013. The intention was to understand the factors associated with marketing authorisation success, the challenges developers face regarding orphan medicine development, and how scientific advice (SA) is used during development. The results demonstrated that orphan medicines have a lower success rate compared with non-orphan medicines and that determinants for marketing authorisation success were company size and compliance with SA. Compliance with SA could help orphan medicine developers overcome clinical development challenges.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs.BMJ Open. 2017 Sep 11;7(9):e017358. doi: 10.1136/bmjopen-2017-017358. BMJ Open. 2017. PMID: 28893754 Free PMC article.
-
Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.Eur J Clin Pharmacol. 2010 Jan;66(1):39-48. doi: 10.1007/s00228-009-0756-y. Epub 2009 Nov 20. Eur J Clin Pharmacol. 2010. PMID: 19936724
-
[Analysis of the evolution in the access to orphan medicines in Spain].Gac Sanit. 2020 Mar-Apr;34(2):141-149. doi: 10.1016/j.gaceta.2019.02.008. Epub 2019 Apr 20. Gac Sanit. 2020. PMID: 31014554 Spanish.
-
[Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].Z Evid Fortbild Qual Gesundhwes. 2013;107(2):120-8. doi: 10.1016/j.zefq.2013.02.003. Epub 2013 Apr 4. Z Evid Fortbild Qual Gesundhwes. 2013. PMID: 23663906 Review. German.
-
Effectiveness, safety and costs of orphan drugs: an evidence-based review.BMJ Open. 2015 Jun 24;5(6):e007199. doi: 10.1136/bmjopen-2014-007199. BMJ Open. 2015. PMID: 26109112 Free PMC article. Review.
Cited by
-
[Evidence-based health care with pharmaceuticals for rare diseases: the role of digitalisation].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Nov;65(11):1170-1177. doi: 10.1007/s00103-022-03605-z. Epub 2022 Oct 20. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022. PMID: 36264322 Free PMC article. Review. German.
-
Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.Eur J Health Econ. 2019 Apr;20(3):427-438. doi: 10.1007/s10198-018-1007-x. Epub 2018 Sep 18. Eur J Health Econ. 2019. PMID: 30229376 Free PMC article.
-
[Orphan drugs from the perspective of the Drug Commission of the German Medical Association : Opportunities and challenges].Internist (Berl). 2019 Apr;60(4):399-404. doi: 10.1007/s00108-019-0578-7. Internist (Berl). 2019. PMID: 30859278 Review. German. No abstract available.
-
Survey of Japanese Orphan Drug Program: Factors Related to Successful Marketing Approval.J Clin Pharmacol. 2020 Jan;60(1):117-124. doi: 10.1002/jcph.1501. Epub 2019 Jul 31. J Clin Pharmacol. 2020. PMID: 31364772 Free PMC article.
-
Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.Orphanet J Rare Dis. 2018 May 11;13(1):77. doi: 10.1186/s13023-018-0820-8. Orphanet J Rare Dis. 2018. PMID: 29751809 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
